Moderna (MRNA) Revenue (2017 - 2026)

Moderna (MRNA) has 10 years of Revenue data on file, last reported at $389.0 million in Q1 2026.

• Revenue for Q1 2026 came in at $389.0 million, up 260.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 billion (down 28.5% YoY), and the FY2025 annual result was $1.9 billion, down 39.93% from the prior year.
• Revenue fell to $389.0 million in Q1 2026 per MRNA's latest filing, from $678.0 million in the prior quarter.
• Over five years, Revenue peaked at $6.1 billion in Q1 2022 and troughed at $108.0 million in Q1 2025.
• A 5-year average of $1.9 billion and a median of $1.0 billion in 2025 frame the typical range for Revenue.
• The sharpest annual moves came in 2023 and 2026: Revenue tumbled 92.76% in 2023, then surged 260.19% in 2026.
• A 5-year view of Revenue shows it stood at $5.1 billion in 2022, then tumbled by 44.71% to $2.8 billion in 2023, then plunged by 65.64% to $966.0 million in 2024, then decreased by 29.81% to $678.0 million in 2025, then sank by 42.63% to $389.0 million in 2026.
• Business Quant data shows MRNA's Revenue at $389.0 million in Q1 2026, $678.0 million in Q4 2025, and $1.0 billion in Q3 2025.